| P/E (FY) | — | Sales (TTM) | SEK 2.4M |
| Earnings (TTM) | -SEK 216.9M | ROE | — |
| Net Margin | −9181.67% | ROIC | −617.99% |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | −36.75% |
Q-linea AB manufactures and sells instruments and consumables used to diagnose and treat infectious diseases, with markets including the United Kingdom, the United States, France, the Middle East, Belgium, Italy, and Finland. Its products include ASTar, an antimicrobial susceptibility testing technology used in treating bloodstream infections and sepsis, along with the associated ASTar BC G- Kit, and it is also developing Podler, a portable blood culture technology. The company serves physicians, hospitals, laboratories, healthcare payers, and the medical profession. It was incorporated in 2007 and is headquartered in Uppsala, Sweden.
| Market Cap | $203.7M | Trading Days | 1778 |
| 52W High | 64.00 |
| 52W Low | 14.55 |
| % Off High | −73.44% |
| YTD | −31.84% | 1Y | −65.24% |
| 3Y | −97.97% | 5Y | −99.92% |
| Since incept. (ann.) | −56.35% |
| Ann. Volatility (1Y) | 60.48% | Ann. Volatility (3Y) | 460.86% |
| Sharpe (1Y) | −1.48 | Sharpe (3Y) | 0.33 |
| Max Drawdown (1Y) | −73.58% | Max Drawdown (3Y) | −98.64% |
| Beta (3Y, vs SPY) | 2.00 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| ANIK | Anika Therapeutics, Inc. | $201.6M | — |
| INFU | InfuSystem Holdings, Inc | $200.2M | 32.0 |
| BCAB | BioAtla, Inc. | $207.7M | — |
| NERV | Minerva Neurosciences, Inc. | $199.4M | — |
| GLSI | Greenwich LifeSciences, Inc. | $197.4M | — |
| RNA | Atrium Therapeutics, Inc. | $196.5M | — |
| INDP | Indaptus Therapeutics, Inc. | $195.9M | — |
| BDSX | BIODESIX INC | $212.6M | — |
| EMBC | Embecta Corp. | $213.0M | 2.2 |
| RJF.MC | LABORATORIO REIG JOFRE S.A. | $214.4M | 20.5 |
| TARA | Protara Therapeutics, Inc. | $214.7M |
| EPRX | EUPRAXIA PHARMACEUTICALS INC. | $217.4M | — |
